NASDAQ: PAHC
Phibro Animal Health Corp Stock

$21.62-0.23 (-1.05%)
Updated Mar 18, 2025
PAHC Price
$21.62
Fair Value Price
-$0.57
Market Cap
$875.69M
52 Week Low
$12.07
52 Week High
$26.55
P/E
45.04x
P/B
3.55x
P/S
0.77x
PEG
0.45x
Dividend Yield
2.22%
Revenue
$1.11B
Earnings
$19.32M
Gross Margin
31.8%
Operating Margin
5.4%
Profit Margin
1.7%
Debt to Equity
4.21
Operating Cash Flow
$56M
Beta
0.84
Next Earnings
May 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A

PAHC Overview

Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine PAHC's potential to beat the market

AStrong Buy
  • Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More

Zen Rating Component Grades

A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Pharmaceutical

Industry Rating
B
PAHC
Ranked
#2 of 58

Top Ranked Stocks in Industry

View Top Pharmaceutical Stocks

Be the first to know about important PAHC news, forecast changes, insider trades & much more!

PAHC News

Overview

Due Diligence Score

Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PAHC scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PAHC ($21.62) is overvalued by 3,873.81% relative to our estimate of its Fair Value price of -$0.57 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PAHC ($21.62) is not significantly undervalued (3,873.81%) relative to our estimate of its Fair Value price of -$0.57 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PAHC ($21.62) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more PAHC due diligence checks available for Premium users.

Valuation

PAHC fair value

Fair Value of PAHC stock based on Discounted Cash Flow (DCF)

Price
$21.62
Fair Value
-$0.57
Undervalued by
3,873.81%
PAHC ($21.62) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PAHC ($21.62) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PAHC ($21.62) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

PAHC price to earnings (PE)

For valuing profitable companies with steady earnings

Company
45.04x
Industry
9.93x
Market
30.9x
PAHC is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PAHC is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

PAHC price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
3.55x
Industry
2.25x
PAHC is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PAHC price to earnings growth (PEG)

For valuing profitable companies with growth potential

PAHC is good value based... subscribe to Premium to read more.
PEG Value Valuation

PAHC's financial health

Profit margin

Revenue
$309.3M
Net Income
$3.2M
Profit Margin
1%
PAHC's Earnings (EBIT) of $59.74M... subscribe to Premium to read more.
Interest Coverage Financials
PAHC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.3B
Liabilities
$1.0B
Debt to equity
4.21
PAHC's short-term assets ($746.15M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PAHC's long-term liabilities ($805.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PAHC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PAHC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$3.1M
Investing
-$260.5M
Financing
$276.3M
PAHC's operating cash flow ($55.54M)... subscribe to Premium to read more.
Debt Coverage Financials

PAHC vs Pharmaceutical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
PAHCA$875.69M-1.05%45.04x3.55x
EOLSC$844.43M-2.28%-16.40x152.92x
AVDLC$833.91M-2.38%-16.92x11.29x
COLLA$938.90M+0.51%13.93x4.10x
HROWC$960.89M+15.69%-28.40x16.57x

Phibro Animal Health Stock FAQ

What is Phibro Animal Health's quote symbol?

(NASDAQ: PAHC) Phibro Animal Health trades on the NASDAQ under the ticker symbol PAHC. Phibro Animal Health stock quotes can also be displayed as NASDAQ: PAHC.

If you're new to stock investing, here's how to buy Phibro Animal Health stock.

What is the 52 week high and low for Phibro Animal Health (NASDAQ: PAHC)?

(NASDAQ: PAHC) Phibro Animal Health's 52-week high was $26.55, and its 52-week low was $12.07. It is currently -18.57% from its 52-week high and 79.12% from its 52-week low.

How much is Phibro Animal Health stock worth today?

(NASDAQ: PAHC) Phibro Animal Health currently has 40,503,608 outstanding shares. With Phibro Animal Health stock trading at $21.62 per share, the total value of Phibro Animal Health stock (market capitalization) is $875.69M.

Phibro Animal Health stock was originally listed at a price of $17.00 in Apr 11, 2014. If you had invested in Phibro Animal Health stock at $17.00, your return over the last 10 years would have been 27.18%, for an annualized return of 2.43% (not including any dividends or dividend reinvestments).

How much is Phibro Animal Health's stock price per share?

(NASDAQ: PAHC) Phibro Animal Health stock price per share is $21.62 today (as of Mar 18, 2025).

What is Phibro Animal Health's Market Cap?

(NASDAQ: PAHC) Phibro Animal Health's market cap is $875.69M, as of Mar 19, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Phibro Animal Health's market cap is calculated by multiplying PAHC's current stock price of $21.62 by PAHC's total outstanding shares of 40,503,608.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.